A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd)

Clinical Trial Details

This clinical trial is for men and women with newly diagnosed multiple myeloma who are not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT).

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

In this study participants will be randomized to receive either teclistamab or talquetamab or daratumumab as subcutaneous (SC) injection in combination with daratumumab and lenalidomide.

Participation is expected to last about 9 years.

Key Eligibility:

Open to men and women above the age of 18 who have been diagnosed with multiple myeloma.
Participants must not have received any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids.

Detailed eligibility will be reviewed when you contact the study team.

Return to List

Study contact by location

Upper East Side - Manhattan

Contact(s)

Kathleen Pogonowski, RN
(646) 962-6500
kap9111@med.cornell.edu

Brooklyn

Contact(s)

June Greenberg, RN
(212) 746-2651
jdg2002@med.cornell.edu

Primary Investigator(s)

Ruben Niesvizky, MD (UES)

Jonathan Canaani, MD (BRK)

Protocol ID(s)

Weill Cornell Medicine IRB #:

2505028822

ClinicalTrials.gov:

NCT05552222

Status

Open to Enrollment

Age Group

Adult

Disease

Multiple Myeloma